Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

Axel Hoos, MD, PhD
Published: Tuesday, Jul 26, 2011



Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that melanoma has often been viewed as a disease that is susceptible to immunotherapy simply because of the various antigens that present in the disease. Hoos goes on to explain that other indications will need to be examined more in depth and could result in another disease that is just as amendable to immunotherapy as melanoma.


Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that melanoma has often been viewed as a disease that is susceptible to immunotherapy simply because of the various antigens that present in the disease. Hoos goes on to explain that other indications will need to be examined more in depth and could result in another disease that is just as amendable to immunotherapy as melanoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x